ArticlePloS one2010
Nuclear entry of activated MAPK is restricted in primary ovarian and mammary epithelial cells.
Article in PloS one, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 38 citations in OpenAlex.
- Targeting colorectal cancer at the level of nuclear pore complex.Journal of advanced research · 2025Review
- Evaluation of the Expression EGFR, HER2/NEU and the End Effector ERK of the RAS/RAF/MAP Kinase Pathway in Prostatic Adenocarcinoma for a Possible Role as New Target Therapy.Asian Pacific journal of cancer prevention : APJCP · 2024Article
- A mass spectrometry-based approach for the identification of Kpnβ1 binding partners in cancer cells.Scientific reports · 2022Article
- The G Protein-Coupled Serotonin 1A Receptor Augments Protein Kinase Cε-Mediated Neurogenesis in Neonatal Mouse Hippocampus-PKCε-Mediated Signaling in the Early Hippocampus.International journal of molecular sciences · 2022Article
- Importin β1 regulates cell growth and survival during adult T cell leukemia/lymphoma therapy.Investigational new drugs · 2021Article
- Immunohistochemical staining of phosphorylated-ERK in post-chemotherapeutic samples is a potential predictor of the prognosis of neuroblastoma.Pediatric surgery international · 2021Article
- Article
- Karyopherins in cancer.Current opinion in cell biology · 2018Review
- KPNβ1 promotes palmitate-induced insulin resistance via NF-κB signaling in hepatocytes.Journal of physiology and biochemistry · 2015Article
- PTN signaling: Components and mechanistic insights in human ovarian cancer.Molecular carcinogenesis · 2015Article
- The nuclear translocation of ERK1/2 as an anticancer target.Nature communications · 2015Article
- Snail promotes epithelial mesenchymal transition in breast cancer cells in part via activation of nuclear ERK2.PloS one · 2014Article
- Importin 7 and Nup358 promote nuclear import of the protein component of human telomerase.PloS one · 2014Article
- The nuclear lamina regulates germline stem cell niche organization via modulation of EGFR signaling.Cell stem cell · 2013Article
- The nuclear envelope environment and its cancer connections.Nature reviews. Cancer · 2012Review
- Importin 7 and exportin 1 link c-Myc and p53 to regulation of ribosomal biogenesis.Molecular cell · 2012Article
- Nuclear extracellular signal-regulated kinase 1 and 2 translocation is mediated by casein kinase 2 and accelerated by autophosphorylation.Molecular and cellular biology · 2011Article
- Casein kinase 2 sends extracellular signal-regulated kinase nuclear.Molecular and cellular biology · 2011Article
- Loss of A-type lamin expression compromises nuclear envelope integrity in breast cancer.Chinese journal of cancer · 2011Article
- Nuclear envelope structural defects cause chromosomal numerical instability and aneuploidy in ovarian cancer.BMC medicine · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundThe MAPK/ERK1/2 serine kinases are primary mediators of the Ras mitogenic signaling pathway. Phosphorylation by MEK activates MAPK/ERK in the cytoplasm, and phospho-ERK is thought to enter the nucleus readily to modulate transcription. PRINCIPAL
findingsHere, however, we observe that in primary cultures of breast and ovarian epithelial cells, phosphorylation and activation of ERK1/2 are disassociated from nuclear translocalization and transcription of downstream targets, such as c-Fos, suggesting that nuclear translocation is limited in primary cells. Accordingly, in import assays in vitro, primary cells showed a lower import activity for ERK1/2 than cancer cells, in which activated MAPK readily translocated into the nucleus and activated c-Fos expression. Primary cells express lower levels of nuclear pore complex proteins and the nuclear transport factors, importin B1 and importin 7, which may explain the limiting ERK1/2 import found in primary cells. Additionally, reduction in expression of nucleoporin 153 by siRNA targeting reduced ERK1/2 nuclear activity in cancer cells.
conclusionERK1/2 activation is dissociated from nuclear entry, which is a rate limiting step in primary cells and in vivo, and the restriction of nuclear entry is disrupted in transformed cells by the increased expression of nuclear pores and/or nuclear transport factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.